Description: GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Home Page: www.genfit.com
GNFT Technical Analysis
Parc EurasantE
Loos,
59120
France
Phone:
33 3 20 16 40 00
Officers
Name | Title |
---|---|
Mr. Jean-Francois Mouney | Co-Founder & Chairman |
Mr. M. Pascal Prigent | Chief Exec. Officer |
Prof. Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board |
Mr. Thomas Baetz | Chief Financial Officer |
Mr. Pascal Caisey | Chief Operating Officer |
Dr. Dean W. Hum Ph.D. | Chief Scientific Officer |
Mr. Laurent Lannoo | Corp. Sec. & Director of Legal Affairs |
Ms. Stefanie Magner | Chief Compliance Officer & VP of International Legal Affairs |
Ms. Emilie Desodt | Vice-Pres of HR |
Mr. Jean-Christophe Marcoux | Chief Strategy Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: |
Forward PE: | 0 |
---|---|
Trailing PE: | 4.8046 |
Price-to-Book MRQ: | 1.5757 |
Price-to-Sales TTM: | 1.9135 |
IPO Date: | 2019-03-27 |
Fiscal Year End: | December |
Full Time Employees: | 134 |